webinar register page

Topic

NAFLDsym v2B Beta Release is Here: Insight into the Next Gen QSP Software Tool in Julia with Blazing Speed and Updated Interfacing

Description

Join us in this webinar to learn about the technical advances made to the NAFLDsym platform in the latest release: version 2B Beta.

Our experts will share details and demonstrations of advances that increase the efficiency with which simulations can be performed in NAFLDsym and improve the user experience. NAFLDsym v2B Beta is built upon a foundation of Julia, providing a substantial boost in simulation speeds. It also employs a user-friendly graphical user interface (GUI) built with Qt that enables users to readily set up, organize, and run simulations individually or in SimPops. These features, along with methods for customizing platform parameters and equations, are among the highlights of this presentation.

Users interested in deploying this updated version will have the opportunity to submit questions for live answers from key developers and early testers. You won’t want to miss this webinar, so register now.

Moderator:
Brett Howell, President DILIsym Services

Presenters:
Scott Q. Siler, Chief Science Officer
Matthew McDaniel, Scientist II
Corey Berry, Senior Software Engineer
Francisco Huizar, Scientist I

Time

Mar 14, 2023 08:00 AM in Pacific Time (US and Canada)

Webinar is over, you cannot register now. If you have any questions, please contact Webinar host: Marketing SimulationsPlus.

All fields are required

Your Information
Send to
Message preview	Hi there, You are invited to a Zoom webinar. When: Mar 14, 2023 08:00 AM Pacific Time (US and Canada) Topic: NAFLDsym v2B Beta Release is Here: Insight into the Next Gen QSP Software Tool in Julia with Blazing Speed and Updated Interfacing Register in advance for this webinar: https://us02web.zoom.us/webinar/register/WN_Ryhk5EVDQ0WrAmd1FlrBsA After registering, you will receive a confirmation email containing information about joining the webinar. ---------- Webinar Speakers Brett Howell (President, DILIsym Services @Simulations Plus) Brett Howell is the President of the DILIsym Services division of Simulations Plus, which is developing and using DILIsym and other software tools to improve the development of safer and more effective drug therapies. He is also an associate director of the DILI-sim Initiative since its inception in 2011. Dr. Howell focuses on company management and operations, sales and marketing, product design, and also helps guide the architecture and consulting use of various QST platforms such as DILIsym and RENAsym. Dr. Howell has published over 30 scientific papers in the areas of PBPK/PD modeling, in vitro toxicity testing, novel drug delivery systems, and drug safety. He has given invited scientific presentations at numerous national and international meetings, including the Society of Toxicology annual meeting, the Japanese Society of Toxicology annual meeting, the annual FDA/AASLD Drug-Induced Liver Injury meeting, and the American Conference on Pharmacometrics (ACOP) annual meeting. Matthew McDaniel (Scientist II @DILIsym Services) Matthew joined the DILIsym team at the start of 2022 as a software developer and quantitative system pharmacology/toxicology (QSP/T) modeler. He is currently assisting in converting the NAFLDsym platform from Matlab to Julia. Matthew first delved into mathematical modeling in biology as a graduate student at North Carolina State University. He helped develop a pharmacokinetic/pharmacodynamic (PKPD) model characterizing intravenous lipid emulsion (ILE) therapy in response to local anesthetic systemic toxicity (LAST) induced by bupivacaine. After graduating, Matthew joined Applied Research Associates (ARA) as a developer on BioGears—a whole-body, physiological modeling and simulation engine. Among the many models he developed for BioGears over the course of three years, his favorite was an inflammation model with application to sepsis and burn pathophysiologies and treatments. Scott Q. Siler (Chief Science Officer @DILIsym Services) Scott Q Siler, Ph.D. is the Chief Scientific Officer of the DILIsym Services division of Simulations Plus. Dr. Siler leads the quantitative systems pharmacology (QSP) and toxicology (QST) efforts within Simulations Plus. On the QSP front, Dr. Siler has led the development and application of NAFLDsym, which has been used to evaluate >25 non-alcoholic steatohepatitis (NASH) compounds and/or targets to date. He has also led the development and application of IPFsym, a QSP model of idiopathic pulmonary fibrosis (IPF), which has been used to evaluate >10 compounds and/or targets to date. Dr. Siler has also led the de novo development of several focused QSP model development efforts to support the development of specific assets across a variety of therapeutic areas for several pharma companies. On the QST side, Scott has led and contributed to the development of DILIsym. Corey Berry (Senior Software Engineer @DILIsym Services) Corey is currently working to convert the current version of the DILIsym modeling software to C++. Mr. Berry has spent over 10 years working with both commercial and government agencies to design, develop and deploy end user software. Corey graduated from the University of Southern Mississippi, with a bachelor of science in computer science and a minor in software engineering. Francisco Huizar (Scientist I @DILIsym Services) Francisco joined DILIsym Services, a division of Simulations Plus in September 2022 as a Scientist I. His primary focus is on development, implementation, and execution of quantitative systems pharmacology (QSP) models within various Simulations Plus platforms (NAFLDsym, IPFsym, and ILDsym). Prior to DILIsym Services, Francisco pursued a PhD in Bioengineering from the University of Notre Dame (anticipated degree conferral in January 2023). In his graduate work, he developed computational models and platforms for understanding multicellular systems biology and advancing preclinical therapeutic screening. He received a research master’s degree in Applied Computational Mathematics and Statistics from the University of Notre Dame. His primary research works involved simulation and implementation of mechanistic models in developing epithelial tissue, development of high-throughput therapeutic screening platforms, and creation of data processing pipelines utilizing machine learning.

Time Zone:

webinar register page

Share via Email

Switch Time Zone

Upcoming Meetings